Immutep Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRRUF research report →
About the company
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
- CEO
- Marc Voigt
- IPO
- 2012
- Employees
- 1,027
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $73.69M
- P/E
- -0.96
- P/S
- 13.56
- P/B
- 0.82
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
- Gross Margin
- -522.59%
- Op Margin
- -2052.18%
- Net Margin
- -1404.13%
- ROE
- -69.20%
- ROIC
- -122.10%
- Revenue
- $5.04M · 31.28%
- Net Income
- $-61,434,165 · -43.82%
- EPS
- $-0.04 · -18.54%
- Op Income
- $-126,421,795
- FCF YoY
- -73.68%
- 52W High
- $0.33
- 52W Low
- $0.04
- 50D MA
- $0.05
- 200D MA
- $0.16
- Beta
- 2.22
- Avg Volume
- 2.79K
Get TickerSpark's AI analysis on PRRUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PRRUF coverage
Recent articles, reports, and earnings notes.
No research on PRRUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRRUF report →Similar companies
Peers in the same neighborhood.